|Dr. Carl Alan Jason Morton Firth||Chairman & CEO||536.51k||N/A||1973|
|Mr. Kiran Asarpota||VP of Fin.||N/A||N/A||1979|
|Dr. Mark McHale||Chief Operating Officer||N/A||N/A||1965|
|Charlie Hsu||Investor Relations Director||N/A||N/A||N/A|
|Mr. Ben Goodger||Gen. Counsel||N/A||N/A||1963|
ASLAN Pharmaceuticals Limited, through its subsidiaries, operates as a clinical-stage oncology-focused biopharmaceutical company, developing therapeutics for global markets. It targets diseases that are highly prevalent in Asia, and orphan indications in the United States and Europe. The company's product pipeline includes Varlitinib, which is being studied in a global pivotal trial (TreeTopp) for biliary tract cancer, and a Phase 2/3 trial for gastric cancer, as well as in a single-arm pivotal clinical trial in biliary tract cancer in China. It has rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses worldwide. The company is also developing ASLAN002, a potent small molecule inhibitor of RON and receptor tyrosine kinases inhibitor for the treatment of gastric and breast cancer; and ASLAN003, a novel DHODH inhibitor, which is in Phase 2 clinical trials to treat acute myeloid leukemia. In addition, it is developing ASLAN004, a monoclonal IL4/IL13 antibody for the treatment of asthma and severe atopic dermatitis. The company has partnerships with Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL. ASLAN Pharmaceuticals Limited was founded in 2010 and is headquartered in Singapore.
ASLAN Pharmaceuticals Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.